MATEs FORUM Forum

FDA in USA Approves Besremi for Adults With Essential Thrombocythemia Diana Ernst, RPh | Publish DateAugust 31, 2026 Ropeginterferon alfa-2b-njft demonstrated a statistically superior durable clinical response over anagrelide in patients with hydroxyurea-resistant or intolerant essential thrombocythemia. The Food and Drug Administration (FDA) has expanded the approval of Besremi® (ropeginterferon alfa-2b-njft) to include the treatment of adults with essential thrombocythemia, a rare blood cancer characterized by the overproduction of platelets. Besremi, a long-acting interferon alfa-2b therapy, previously received approval for the treatment of polycythemia vera in 2021. Approval in patients with essential thrombocythemia was supported by data from the phase 3 SURPASS-ET trial (ClinicalTrials.gov Identifier: NCT04285086). Study participants with documented resistance or intolerance to hydroxyurea were randomly assigned to receive ropeginterferon alfa-2b subcutaneously every 2 weeks (n=91) or oral anagrelide daily (n=83). The primary endpoint was durable clinical response measured using modified European Leukemia Net (ELN) criteria at months 9 and 12. Response criteria included a reduction in peripheral blood counts (platelets ≤400×10⁹/L and white blood cells <9.5×10⁹/L), an improvement or no worsening in disease-related signs (splenomegaly), and no bleeding or thrombotic events. Findings showed treatment with ropeginterferon alfa-2b led to a significantly higher response rate

FDA in USA Approves Besremi for Adults With Essential Thrombocythemia Diana Ernst, RPh | Publish DateAugust 31, 2026 Ropeginterferon alfa-2b-njft demonstrated a statistically superior durable clinical response over anagrelide in patients with hydroxyurea-resistant or intolerant essential thrombocythemia. The Food and Drug Administration (FDA) has expanded the approval of Besremi® (ropeginterferon alfa-2b-njft) to include the treatment of adults with essential thrombocythemia, a rare blood cancer characterized by the overproduction of platelets. Besremi, a long-acting interferon alfa-2b therapy, previously received approval for the treatment of polycythemia vera in 2021. Approval in patients with essential thrombocythemia was supported by data from the phase 3 SURPASS-ET trial (ClinicalTrials.gov Identifier: NCT04285086). Study participants with documented resistance or intolerance to hydroxyurea were randomly assigned to receive ropeginterferon alfa-2b subcutaneously every 2 weeks (n=91) or oral anagrelide daily (n=83). The primary endpoint was durable clinical response measured using modified European Leukemia Net (ELN) criteria at months 9 and 12. Response criteria included a reduction in peripheral blood counts (platelets ≤400×10⁹/L and white blood cells <9.5×10⁹/L), an improvement or no worsening in disease-related signs (splenomegaly), and no bleeding or thrombotic events. Findings showed treatment with ropeginterferon alfa-2b led to a significantly higher response rate

FDA in USA Approves Besremi for Adults With Essential Thrombocythemia Diana Ernst, RPh | Publish DateAugust 31, 2026 Ropeginterferon alfa-2b-njft demonstrated a statistically superior durable clinical response over anagrelide in patients with hydroxyurea-resistant or intolerant essential thrombocythemia. The Food and Drug Administration (FDA) has expanded the approval of Besremi® (ropeginterferon alfa-2b-njft) to include the treatment of adults with essential thrombocythemia, a rare blood cancer characterized by the overproduction of platelets. Besremi, a long-acting interferon alfa-2b therapy, previously received approval for the treatment of polycythemia vera in 2021. Approval in patients with essential thrombocythemia was supported by data from the phase 3 SURPASS-ET trial (ClinicalTrials.gov Identifier: NCT04285086). Study participants with documented resistance or intolerance to hydroxyurea were randomly assigned to receive ropeginterferon alfa-2b subcutaneously every 2 weeks (n=91) or oral anagrelide daily (n=83). The primary endpoint was durable clinical response measured using modified European Leukemia Net (ELN) criteria at months 9 and 12. Response criteria included a reduction in peripheral blood counts (platelets ≤400×10⁹/L and white blood cells <9.5×10⁹/L), an improvement or no worsening in disease-related signs (splenomegaly), and no bleeding or thrombotic events. Findings showed treatment with ropeginterferon alfa-2b led to a significantly higher response rate

FDA in USA Approves Besremi for Adults With Essential Thrombocythemia Diana Ernst, RPh | Publish DateAugust 31, 2026 Ropeginterferon alfa-2b-njft demonstrated a statistically superior durable clinical response over anagrelide in patients with hydroxyurea-resistant or intolerant essential thrombocythemia. The Food and Drug Administration (FDA) has expanded the approval of Besremi® (ropeginterferon alfa-2b-njft) to include the treatment of adults with essential thrombocythemia, a rare blood cancer characterized by the overproduction of platelets. Besremi, a long-acting interferon alfa-2b therapy, previously received approval for the treatment of polycythemia vera in 2021. Approval in patients with essential thrombocythemia was supported by data from the phase 3 SURPASS-ET trial (ClinicalTrials.gov Identifier: NCT04285086). Study participants with documented resistance or intolerance to hydroxyurea were randomly assigned to receive ropeginterferon alfa-2b subcutaneously every 2 weeks (n=91) or oral anagrelide daily (n=83). The primary endpoint was durable clinical response measured using modified European Leukemia Net (ELN) criteria at months 9 and 12. Response criteria included a reduction in peripheral blood counts (platelets ≤400×10⁹/L and white blood cells <9.5×10⁹/L), an improvement or no worsening in disease-related signs (splenomegaly), and no bleeding or thrombotic events. Findings showed treatment with ropeginterferon alfa-2b led to a significantly higher response rate

Afternoon all... Just a quick message to let you know we will be having our Six (6) weekly MATES Cafe Catchup this Sunday, (tomorrow night) Here's the Link for anyone that might like to come along and join us etc... Hope to be discussing the problems with Raynaud's & the benefits of having an MPN Booklet? See you there... Steve MPN MATES Admin MATES CAFE CATCHUP MEETING DETAILS: TIME: Sunday 30 AUGUST 2026 TIME: 18:00 - 19:00 (AEST) Meeting link: MatesRF TBA invited you to a Microsoft Teams Meeting: MATES CAFE CATCHUP Sunday 30 August 2026 18:00 - 19:00 (AEST) Meeting link: https://teams.live.com/meet/93988408100 ... wjucP8Nynx

Afternoon all... Just a quick message to let you know we will be having our Six (6) weekly MATES Cafe Catchup this Sunday, (tomorrow night) Here's the Link for anyone that might like to come along and join us etc... Hope to be discussing the problems with Raynaud's & the benefits of having an MPN Booklet? See you there... Steve MPN MATES Admin MATES CAFE CATCHUP MEETING DETAILS: TIME: Sunday 30 AUGUST 2026 TIME: 18:00 - 19:00 (AEST) Meeting link: MatesRF TBA invited you to a Microsoft Teams Meeting: MATES CAFE CATCHUP Sunday 30 August 2026 18:00 - 19:00 (AEST) Meeting link: https://teams.live.com/meet/93988408100 ... wjucP8Nynx

Afternoon all... Just a quick message to let you know we will be having our Six (6) weekly MATES Cafe Catchup this Sunday, (tomorrow night) Here's the Link for anyone that might like to come along and join us etc... Hope to be discussing the problems with Raynaud's & the benefits of having an MPN Booklet? See you there... Steve MPN MATES Admin MATES CAFE CATCHUP MEETING DETAILS: TIME: Sunday 30 AUGUST 2026 TIME: 18:00 - 19:00 (AEST) Meeting link: MatesRF TBA invited you to a Microsoft Teams Meeting: MATES CAFE CATCHUP Sunday 30 August 2026 18:00 - 19:00 (AEST) Meeting link: https://teams.live.com/meet/93988408100 ... wjucP8Nynx

Afternoon all... Just a quick message to let you know we will be having our Six (6) weekly MATES Cafe Catchup this Sunday, (tomorrow night) Here's the Link for anyone that might like to come along and join us etc... Hope to be discussing the problems with Raynaud's & the benefits of having an MPN Booklet? See you there... Steve MPN MATES Admin MATES CAFE CATCHUP MEETING DETAILS: TIME: Sunday 30 AUGUST 2026 TIME: 18:00 - 19:00 (AEST) Meeting link: MatesRF TBA invited you to a Microsoft Teams Meeting: MATES CAFE CATCHUP Sunday 30 August 2026 18:00 - 19:00 (AEST) Meeting link: https://teams.live.com/meet/93988408100 ... wjucP8Nynx

Hello everyone, I hope you’re all doing well. I just wanted to pop in and let you know that I have a couple of sleep and relaxation meditations available if anyone would like to listen. I know how difficult it can sometimes be to switch off, especially when living with an MPN, so I thought I’d share them here in case they might bring someone a little comfort, calm or rest. https://youtu.be/NVMUX7uk6tQ https://youtu.be/27mgDcPW_mY https://youtu.be/oD_OrTORtu8 https://youtu.be/om5OXI_ZoP8 Sending lots of warmth to you all. Amanda xx

Hello everyone, I hope you’re all doing well. I just wanted to pop in and let you know that I have a couple of sleep and relaxation meditations available if anyone would like to listen. I know how difficult it can sometimes be to switch off, especially when living with an MPN, so I thought I’d share them here in case they might bring someone a little comfort, calm or rest. https://youtu.be/NVMUX7uk6tQ https://youtu.be/27mgDcPW_mY https://youtu.be/oD_OrTORtu8 https://youtu.be/om5OXI_ZoP8 Sending lots of warmth to you all. Amanda xx

Hello everyone, I hope you’re all doing well. I just wanted to pop in and let you know that I have a couple of sleep and relaxation meditations available if anyone would like to listen. I know how difficult it can sometimes be to switch off, especially when living with an MPN, so I thought I’d share them here in case they might bring someone a little comfort, calm or rest. https://youtu.be/NVMUX7uk6tQ https://youtu.be/27mgDcPW_mY https://youtu.be/oD_OrTORtu8 https://youtu.be/om5OXI_ZoP8 Sending lots of warmth to you all. Amanda xx

Hello everyone, I hope you’re all doing well. I just wanted to pop in and let you know that I have a couple of sleep and relaxation meditations available if anyone would like to listen. I know how difficult it can sometimes be to switch off, especially when living with an MPN, so I thought I’d share them here in case they might bring someone a little comfort, calm or rest. https://youtu.be/NVMUX7uk6tQ https://youtu.be/27mgDcPW_mY https://youtu.be/oD_OrTORtu8 https://youtu.be/om5OXI_ZoP8 Sending lots of warmth to you all. Amanda xx